drugset / Trial / NCT02519439

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439

Phase 3 Terminated 26 enrolled Marinus Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures

Timeline

Start
2015-02
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule 450 mg
Subject Ganaxolone Small molecule 900 mg